Phase 1 Trial of the Mammalian Target of Rapamycin (mTOR) Inhibitor Everolimus Plus Radiation Therapy (RT) for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following Prostatectomy

NCT01548807 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

19

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer Patients With Detectable PSA Following Prostatectomy

Interventions

DRUG: Everolimus (RAD001)

Sponsor

Abramson Cancer Center at Penn Medicine